A retrospective analysis of optimal timing of thoracic radiotherapy for driver gene ‐negative metastatic non‐small cell lung cancer

ConclusionThe addition of TRT during the pre-emptive no progression phase was associated with a significantly longer PFS than during the delayed slow progression phase and had an acceptable safety profile. Our results might support the earlier initiation of TRT after induction therapy for some patients with driver-gene-negative mNSCLC.

Source: Thoracic Cancer - February 7, 2024 Category: Cancer & Oncology Authors: Yanan Wang, Zhenhua Gao, Wen Zhao, Hongxin Li, Xue Meng, Jisheng Li Tags: ORIGINAL ARTICLE Source Type: research